Should Bladder Cuff Excision Remain the Standard of Care at Nephroureterectomy in Patients with Urothelial Carcinoma of the Renal Pelvis? A Population-based Study

被引:81
作者
Lughezzani, Giovanni [1 ,2 ]
Sun, Maxine [1 ]
Perrotte, Paul [3 ]
Shariat, Shahrokh F. [1 ]
Jeldres, Claudio [1 ]
Budaus, Lars [1 ,4 ]
Alasker, Ahmed [1 ]
Duclos, Alain [3 ]
Widmer, Hugues [3 ]
Latour, Mathieu [5 ]
Guazzoni, Giorgio [2 ]
Montorsi, Francesco [2 ]
Karakiewicz, Pierre I. [1 ,3 ]
机构
[1] Univ Montreal, Canc Prognost & Hlth Outcomes Unit, Ctr Hlth, Montreal, PQ H2X 3J4, Canada
[2] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy
[3] Univ Montreal, Dept Urol, Montreal, PQ H2X 3J4, Canada
[4] Prostate Canc Ctr Hamburg Eppendorf, Martini Clin, Hamburg, Germany
[5] Univ Montreal, Dept Pathol, Montreal, PQ H2X 3J4, Canada
关键词
Urothelial carcinoma; Upper urinary tract; Nephroureterectomy; Survival; UPPER URINARY-TRACT; DISTAL URETER; LAPAROSCOPIC NEPHROURETERECTOMY; RADICAL NEPHROURETERECTOMY; REGISTRY DATA; CANCER; MANAGEMENT; SURVIVAL; OUTCOMES;
D O I
10.1016/j.eururo.2009.12.001
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: A large, multi-institutional, tertiary care center study suggested no benefit from bladder cuff excision (BCE) at nephroureterectomy in patients with upper tract urothelial carcinoma (UC). Objective: We tested and quantified the prognostic impact of BCE at nephroureterectomy on cancer-specific mortality (CSM) in a large population-based cohort of patients with UC of the renal pelvis. Design, setting, and participants: A cohort of 4210 patients with UC of the renal pelvis were treated with nephroureterectomy with (NUC) or without (NU) a BCE between 1988 and 2006 within 17 Surveillance, Epidemiology, and End Results registries. Measurements: Cumulative incidence plots and competing risks regression models compared CSM after either NUC or NU. Covariates consisted of pathologic T and N stages, grade, age, year of surgery, gender, and race. Results and limitations: Respectively, 2492 (59.2%) and 1718 (40.8%) patients underwent a nephroureterectomy with or without BCE. In univariable and multivariable analyses, BCE omission increased CSM rates in patients with pT3N0/x, pT4N0/x, and pT(any)N1-3 UC of the renal pelvis. For example, in patients with pT3N0/x disease, holding all other variables constant, BCE omission increased CSM in a 1.25-fold fashion (p = 0.04). Similarly, in patients with pT4N0/x disease, BCE omission resulted in a 1.45-fold increase (p = 0.02). The main limitation of our study is the lack of data on disease recurrence. Conclusions: Nephroureterectomy with BCE remains the standard of care in the treatment of UC of the renal pelvis and should invariably be performed in patients with locally advanced disease. Conversely, patients with pT1 and pT2 disease could be considered for NU without compromising CSM. However, recurrence data are needed to fully confirm the validity of this option. Crown Copyright (C) 2009 Published by Elsevier B. V. on behalf of European Association of Urology. All rights reserved.
引用
收藏
页码:956 / 962
页数:7
相关论文
共 24 条
[1]  
[Anonymous], 2005, PROGR AUTOIMM DIS RE
[2]  
[Anonymous], NCCN CLIN PRACT GUID
[3]   Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases [J].
Capitanio, Umberto ;
Shariat, Shahrokh F. ;
Isbarn, Hendrik ;
Weizer, Alon ;
Remzi, Mesut ;
Roscigno, Marco ;
Kikuchi, Eiji ;
Raman, Jay D. ;
Bolenz, Christian ;
Bensalah, Karim ;
Koppie, Theresa M. ;
Kassouf, Wassim ;
Fernandez, Mario I. ;
Stroebel, Philipp ;
Wheat, Jeffrey ;
Zigeuner, Richard ;
Langner, Cord ;
Waldert, Matthias ;
Oya, Mototsugu ;
Guo, Charles C. ;
Ng, Casey ;
Montorsi, Francesco ;
Wood, Christopher G. ;
Margulis, Vitaly ;
Larakiewicz, Pierre I. .
EUROPEAN UROLOGY, 2009, 56 (01) :1-9
[4]  
Cooper GS, 2002, MED CARE, V40, P43
[5]   Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment [J].
Cooper, GS ;
Yuan, Z ;
Stange, KC ;
Dennis, LK ;
Amini, SB ;
Rimm, AA .
MEDICAL CARE, 2000, 38 (04) :411-421
[6]   Estimating Breast Cancer-Specific and Other-Cause Mortality in Clinical Trial and Population-Based Cancer Registry Cohorts [J].
Dignam, James J. ;
Huang, Lan ;
Ries, Lynn ;
Reichman, Marsha ;
Mariotto, Angela ;
Feuer, Eric .
CANCER, 2009, 115 (22) :5272-5283
[7]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[8]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[9]   Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration [J].
Hellenthal, Nicholas J. ;
Shariat, Shahrokh F. ;
Margulis, Vitaly ;
Karakiewicz, Pierre I. ;
Roscigno, Marco ;
Bolenz, Christian ;
Remzi, Mesut ;
Weizer, Alon ;
Zigeuner, Richard ;
Bensalah, Karim ;
Ng, Casey K. ;
Raman, Jay D. ;
Kikuchi, Eiji ;
Montorsi, Francesco ;
Oya, Mototsugu ;
Wood, Christopher G. ;
Fernandez, Mario ;
Evans, Christopher P. ;
Koppie, Theresa M. .
JOURNAL OF UROLOGY, 2009, 182 (03) :900-906
[10]   Carcinoma of the Upper Urinary Tract Predictors of Survival and Competing Causes of Mortality [J].
Inman, Brant A. ;
Tran, Viet-Tan ;
Fradet, Yves ;
Lacombe, Louis .
CANCER, 2009, 115 (13) :2853-2862